Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

Update on the Management of COPD

This month, E. Neil Schachter, M.D. discusses
CME credit is no longer available for this conference.

Course Authors

E. Neil Schachter, M.D.

Dr. Schachter reports no commercial conflict of interest.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Delineate pathophysiologic elements of COPD that determine approaches to therapy

  • List potential advantages/indications for the use of stereisomer specific beta agonists in COPD

  • Describe the role of corticosteroids in COPD.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

Cystic Fibrosis -- No Longer Just a Disease of Pediatric Medicine

Emerging research suggests target-specific therapies for managing cystic fibrosis.
Authors: Arindam Singha, M.D., and Stephen E. Kirkby, M.D.
Estimated Time: 1 Hour
More

Asthma Management: A Multi-Faceted Approach

Asthma action plans are designed to be individualized and developed jointly with the patient, and may be based on symptoms or peak flow measurements.
Authors: Cathy G. Benninger, R.N., M.S., C.N.P., and Jennifer W. McCallister, M.D.
Estimated Time: 1 Hour
More

Idiopathic Pulmonary Fibrosis

Table 1. Clinical Strategies for the Improvement of Asthma Control.
Authors: Ganesh Raghu, M.D., and Samuel G. Rayner, M.D.
Estimated Time: 2 Hours
More

The Role of Matrix Metalloproteinases (MMPs) in COPD

Elaboration of matrix metalloproteinases (MMPs), zinc-dependent proteases, within the airways contributes to COPD.
Authors: Robert Foronjy, M.D., and Jeanine D'Armiento, M.D., Ph.D.
Estimated Time: 1 Hour
More

Acute Lung Injury and the Acute Respiratory Distress Syndrome

ALI complicates a variety of medical and surgical conditions, most commonly severe sepsis, pneumonia and massive trauma.
Authors: Chirag V. Shah, M.D., M.S., and Jason D. Christie, M.D., M.S.
Estimated Time: 1 Hour
More

The Diagnosis and Management of Venous Thromboembolism

This month, Victor F. Tapson, M.D., discusses

present in acute PE. The diagnostic utility of plasma measurements of circulating D-dimer (a specific derivative of cross-linked fibrin) has been extensively evaluated in patients with PE. A number of D-dimer assays are available, and the sensitivity and specificity of these assays vary. A positive D-dimer test means that
Authors: Victor F. Tapson, M.D.
Estimated Time: 1 Hour
More